所属していた研究者名は下線で示しています　　　　　　　　　　The researchers, working in this lab, are underlined

1. Mazzocca A, Dituri F, De Santis F, Filannino A, Lopane C, Betz RC, Li Y-Y, Mukaida N, Winter P, Tortorella C, Giannelli G, and Sabba C. Lysophatidic acid receptor LPAR6 supports the tumorigenecity of hepatocellular carcinoma. Cancer Res 2014; 75(3): 532-543. doi: 10.1158/0008-5472.CAN-14-6407. (Abstract)

2. Song Y, Baba T, Li Y-Y, Furukawa K, Tanabe Y, Matsugo S, Sasaki S, and Mukaida N. Gemcitabine-induced CXCL8 epxression counteracts its action by inducing tumor neovascularization. Biochem Biophys Res Comm 2014; 458 (2): 341-346. doi: 10.1016/j.bbrc.2015.01.112. (Abstract)

3. Hata R, Isukuri K, Kato Y, Sasaki S, Mukaida N, Maehata Y, Miyamoto C, Akasaka T, Yang X, Nagashima Y, Takeda K, Kiyono T and Taniguchi M. Suppressed rate of carcinogenesisi and decrease in tumor volumes and lung metastasis in CXCL14/BRAK transgenic mice. Sci Rep 2015; 5: 9083. doi: 10. 103/8/srep09083. (Abstract) (Free full-text).

4. Liang C, Yu X-J, Guo X-Z, Sun M-H, Wang Z, Song Y, Ni Q-X, Li H-Y, Mukaida N, and Li Y-Y. MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreactic cancer cells sensitive to gemcitabine. Oncotarget 2015; 6 (16): 14440-14455. (Abstract) (Free full-text).

5. Naito T, Baba T, Takeda K, Sasaki S, Nakamoto Y, and Mukaida N. High-dose cyclophosphamide induces specific tumor immunity with concomitant recruitment of LAMP1/CD107a-expressing CD4-positive T cells into tumor sites. Cancer Lett 2015; 366 (1): 93-99 doi: 10.1016/j.canlet.2015.06.009 (Abstract)

６． Nakano H, Hasegawa T, Saito N, Furukawa K, Mukaida N, Kojima H, Okabe T, and Nagano T. Design and synthesis of an in-vivo efficacious PIM3 kinase inhibitor as a candidate anti-pancreactic cancer agent. Biogarnic Med Chem Lett 2015; 25: 5687-5693. doi. 10.1016/j.bmcl.2015.10.098. (Abstract)